{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:26:33Z","timestamp":1782253593389,"version":"3.54.5"},"reference-count":65,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T00:00:00Z","timestamp":1379980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:p>Clostridium difficile is a gram-negative, anaerobic, spore-forming emerging pathogen within health care systems and community-based populations that has a high associated morbidity and mortality as well as cost for the health care system. Recent studies reported high rates of recurrence thus a need for new pharmacological agents to treat C difficile infections (CDIs). Fidaxomicin is a novel macrocyclic antibiotic, originally isolated from fermentation broth of Dactylosporangium aurantiacum spp Hamdenensis, with selective spectrum, unique pharmacokinetic and pharmacodynamics profile, adverse effect profile, efficacy, and role in the treatment of and time to recurrent CDI. Fidaxomicin data have similar clinical cure, when compared to vancomycin, with lower recurrence rates and higher global cure rates in non-BI\/NAP1\/027 strains. Fidaxomicin also lacks activity against gram-negative bacteria; hence, its potential effect on resistance development among enteric bacteria appears to be low. It appears to have minimal need for renal or hepatic adjustments and minimal concerns for drug\u2013drug interactions. Overall, fidaxomicin has been generally well tolerated with the most common adverse effects reported as mild gastrointestinal complaints. Fidaxomicin appears to have a role in the treatment of CDI with potential lower rates of recurrence, especially in patients with severe disease or risk factors for recurrent CDI.<\/jats:p>","DOI":"10.1177\/0897190013499526","type":"journal-article","created":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T15:45:20Z","timestamp":1380037520000},"page":"491-497","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of Fidaxomicin for the Treatment of\n                    <i>Clostridium difficile<\/i>\n                    Infection"],"prefix":"10.1177","volume":"26","author":[{"given":"Paul","family":"Juang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, St Louis College of Pharmacy, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Hardesty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Baton Rouge General Medical Center, Baton Rouge, LA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,9,24]]},"reference":[{"key":"bibr1-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/651706"},{"key":"bibr2-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.08.002"},{"issue":"47","key":"bibr3-0897190013499526","first-page":"1201","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr4-0897190013499526","doi-asserted-by":"publisher","DOI":"10.2307\/30145589"},{"key":"bibr5-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051590"},{"key":"bibr6-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/501126"},{"key":"bibr7-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2008.08.012"},{"key":"bibr8-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.13.1407"},{"key":"bibr9-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-08"},{"key":"bibr10-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70215-2"},{"key":"bibr11-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/430311"},{"key":"bibr12-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/430315"},{"key":"bibr13-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/519265"},{"key":"bibr14-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05839.x"},{"key":"bibr15-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01539.x"},{"key":"bibr16-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225685.37465.e7"},{"key":"bibr17-0897190013499526","first-page":"74","volume":"5","author":"Borero M","year":"1990","journal-title":"Microbiol Med"},{"key":"bibr18-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/599224"},{"key":"bibr19-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/511870"},{"key":"bibr20-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2006.06.007"},{"key":"bibr21-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl553"},{"key":"bibr22-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205037"},{"key":"bibr23-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"bibr24-0897190013499526","unstructured":"Crook D, Weiss K, Cornely OA, Randomized clinical trial in\n                      Clostridium difficile\n                      infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin. In: 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010; Vienna, Austria."},{"key":"bibr25-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis499"},{"key":"bibr26-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2280-2282.2004"},{"key":"bibr27-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.11.4430-4434.2004"},{"key":"bibr28-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4898-4902.2004"},{"key":"bibr29-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"bibr30-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00476-08"},{"key":"bibr31-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1108"},{"key":"bibr32-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.33.3.945-953.1980"},{"key":"bibr33-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/JB.132.1.73-79.1977"},{"key":"bibr34-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00104-11"},{"key":"bibr35-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.029470-0"},{"key":"bibr36-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-07"},{"key":"bibr37-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2009.09.005"},{"key":"bibr38-0897190013499526","unstructured":"Babakhani F, Shangle S, Robert N, Resistance development, cross-resistance, and synergy studies of OPT-80. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC."},{"key":"bibr39-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis453"},{"key":"bibr40-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis338"},{"key":"bibr41-0897190013499526","unstructured":"Okumu F, Walsh RB, Sears P, Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of\n                      Clostridium difficile\n                      associated diarrhea. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC."},{"key":"bibr42-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis337"},{"key":"bibr43-0897190013499526","volume-title":"Dificid (Fidaxomicin) Prescribing Information","author":"Optimer Pharmaceuticals I","year":"2012"},{"key":"bibr44-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01443-07"},{"key":"bibr45-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01442-07"},{"key":"bibr46-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"bibr47-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(09)60516-3"},{"key":"bibr48-0897190013499526","unstructured":"Golan Y, Mullane KM, Miller MA, Low recurrence rate among patients with\n                      C. difficile\n                      infection treated with fidaxomicin. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco, CA."},{"key":"bibr49-0897190013499526","unstructured":"Miller MA, Mullane KM, Weiss K, Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with\n                      Clostridium difficile\n                      infection (CDI). In: 47th Annual Meeting of the Infectious Diseases Society of America; 2009; Philadelphia, PA."},{"key":"bibr50-0897190013499526","unstructured":"Mullane KM, Miller MA, Weiss K, Effect of concomitant antibiotics on treatment of\n                      Clostridium difficile\n                      (CDI) infection with fidaxomicin or vancomycin. In: 47th Annual Meeting of the Infectious Diseases Society of America; 2009; Philadelphia, PA."},{"key":"bibr51-0897190013499526","unstructured":"Crook D, Peto T, Miller M, Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in\n                      Clostridium difficile\n                      infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients. In: 48th Annual Meeting of the Infectious Diseases Society of America; 2010; Vancouver, British Columbia, Canada."},{"key":"bibr52-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis462"},{"key":"bibr53-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir404"},{"key":"bibr54-0897190013499526","unstructured":"Gerding DN, Sambol SP, Nagaro K,\n                      Clostridium difficile\n                      strain type as determined by restriction endonuclease analysis (REA) in two phase III trials of fidaxomicin vs vancomycin: treatment outcome for the epidemic BI\/NAP1\/027 strain. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010; Boston, MA."},{"key":"bibr55-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.5899"},{"key":"bibr56-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/506387"},{"key":"bibr57-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.007"},{"key":"bibr58-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01842-09"},{"key":"bibr59-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.1.36"},{"key":"bibr60-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199509000-00008"},{"key":"bibr61-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1086\/338260"},{"key":"bibr62-0897190013499526","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110371"},{"key":"bibr63-0897190013499526","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261906"},{"key":"bibr64-0897190013499526","doi-asserted-by":"publisher","DOI":"10.2146\/news120070"},{"key":"bibr65-0897190013499526","unstructured":"Optimer patient assistance program. http:\/\/www.dificid.com\/patient-and-caregiver-resources\/patient-assistance-program. Accessed January 29, 2013."}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190013499526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190013499526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190013499526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:35:14Z","timestamp":1777509314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190013499526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,24]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1177\/0897190013499526"],"URL":"https:\/\/doi.org\/10.1177\/0897190013499526","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,24]]}}}